Tempus AI, Inc. TEM
Tempus AI is an AI-branded diagnostics roll-up whose tiny AI revenue, Lefkofsky-linked restatement history, and round-tripped related-party deals imply 50-60% downside to ~$25-34/share.
Thesis
Spruce Point issues a Strong Sell on Tempus AI (NASDAQ: TEM), arguing the rebrand from Tempus Labs is a promotional repackaging: AI revenue was just $12.4M in 2024, under 2% of the $693M total. CEO Eric Lefkofsky and partner Brad Keywell have a track record of shareholder destruction at Starbelly/HA-LO, Groupon and InnerWorkings, and the audit committee, CAO and directors are linked to multiple restatements and SEC fraud cases. Spruce Point flags a $250M Google Cloud debt-forgiveness structure inflating Adjusted EBITDA by 320bps, a $200M Pathos/AstraZeneca deal that looks like round-tripping through a Lefkofsky-related party, a SoftBank JV recycling contributed capital as revenue, and ~$600M of inflated Total Contract Value. Insider selling, rising debt post-Ambry and a 77%-of-revenue stock-comp burn imply 50-60% downside versus the current $65.87 share price.
SCQA
Tempus AI (NASDAQ: TEM) is a $12bn precision-medicine company rebranded from Tempus Labs, pitching itself as an AI-driven diagnostics and data platform led by Groupon founder Eric Lefkofsky.
Only ~2% of revenue is AI-derived, the CEO, CAO, audit chair and directors are tied to prior restatements and SEC fraud cases, and growth rests on round-tripped related-party deals, a Google debt cookie jar, and inflated TCV.
Spruce Point issues a 'Strong Sell' opinion, urging investors to discount headline TCV and Adjusted EBITDA, scrutinize Pathos/AstraZeneca, SoftBank JV and Google Cloud accounting, and reassess the AI narrative.
Valuing core, acquired and related-party revenue separately yields an implied $24.87-$34.15 share price versus $65.87, implying 48-62% downside (base-case mid ~50-60%).
The three reasons
- 1
AI branding masks reality: AI revenue only $12.4M, under 2% of $693M total
- 2
Management and board tied to prior restatements, bankruptcies and SEC fraud cases
- 3
TCV inflated ~$600M via opt-ins, round-tripped JV cash and related-party Pathos deal
Primary demands
- Investors should sell or avoid TEM shares; Spruce Point issues a 'Strong Sell' opinion
- Scrutinize aggressive accounting around Total Contract Value, Google Cloud debt forgiveness and related-party deals
- Question board and audit committee oversight given insiders' ties to prior restatements and SEC fraud cases
- Reassess AI branding claims against minimal AI-derived revenue (~2% of total)
KPIs cited
Pattern membership
Precedents cited
- InnerWorkings (INWK) — Lefkofsky/Keywell promotion, restatement and -92% decline
- Starbelly.com / HA-LO Industries (HMK) — dotcom-era Lefkofsky/Keywell venture that filed for bankruptcy
- Groupon (GRPN) — prior Lefkofsky promotion, ~50% revenue restatement and -95% post-IPO decline
- C3.ai (AI) — prior Spruce Point AI-hype short with -60% drawdown
- AOL Time Warner — SEC revenue round-tripping case involving director Ted Leonsis
- Vonage (VG) — restatement under audit-committee member Peter Barris
- GeneDx / Sema4 (WGS) — Grizzly Research fraud allegations tied to Pathos CSO
Composition what's on the 76 slides
Slide gallery ·
Notes
Classic Spruce Point short report template: teal/grey Spruce Point branding, yellow call-out boxes, red-flag icons for 'Top 5 Concerns', pattern-match to prior Spruce Point campaigns (C3.ai, InnerWorkings) used as credibility precedents. Cover page is a stylized 'storm over tickers' image linking TEM to past shorts (INWK, HMK, GRPN). Heavy use of Lefkofsky's 2000 'let's be WILDLY positive... THE TIME TO GET RADICAL IS NOW' email as CEO-quote-contradiction evidence. Sum-of-parts on p.76 splits core/related-party/Ambry revenue. Stake % not disclosed (Spruce Point typically runs short positions without 13D-style quantification). Author_name null — document signed institutionally as 'Spruce Point Capital Management' with no individual signatory. Campaign phase coded as initial_thesis since this is Spruce Point's first public TEM report.